NCT06732895View on ClinicalTrials.gov

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Achondroplasia
Interventions
DRUG

Navepegritide

Once-weekly subcutaneous injection of 100 µg/kg navepegritide for 52 weeks

DRUG

Placebo for navepegritide

Once-weekly subcutaneous injection of 100 µg/kg placebo for navepegritide

Trial Locations (2)

2100

RECRUITING

Ascendis Investigational Site, Copenhagen

75743

RECRUITING

Ascendis Investigational Site, Paris

Sponsors
All Listed Sponsors
lead

Ascendis Pharma A/S

INDUSTRY